HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Contact
2929 N. Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
stocks
Why great earnings haven't been good enough for AI hardware stocks
stocks
Fair Value increased for Big 4 bank after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,313.20 | 19.60 | -0.21% |
| CAC 40 | 8,639.70 | 10.86 | -0.13% |
| DAX 40 | 26,433.19 | 133.45 | 0.51% |
| Dow JONES (US) | 53,745.46 | 94.53 | -0.18% |
| FTSE 100 | 10,753.27 | 19.40 | -0.18% |
| HKSE | 25,116.85 | 279.66 | -1.10% |
| NASDAQ | 26,710.40 | 92.63 | -0.35% |
| Nikkei 225 | 68,713.80 | 405.20 | 0.59% |
| NZX 50 Index | 13,854.38 | 29.08 | 0.21% |
| S&P 500 | 7,787.50 | 11.49 | -0.15% |
| S&P/ASX 200 | 9,115.20 | 19.90 | -0.22% |
| SSE Composite Index | 3,927.18 | 0.21 | 0.01% |